Diverse muscarinic allosteric ligands exhibit greatest affinity toward the M 2 receptor subtype and lowest affinity toward M 5 . In this study, we evaluated the potencies with which two groups of highly M 2 /M 5 selective allosteric agents modulate the dissociation of [
The five subtypes of muscarinic acetylcholine receptors are members of the superfamily of G protein-coupled receptors. The binding site for acetylcholine and conventional agonists and antagonists on muscarinic receptors seems to be located within a pocket formed by the seven ␣-helical transmembrane domains characteristic of all G protein-coupled receptors (Hulme et al., 1990; Wess, 1993) . There is a high degree of conservation of amino acid sequence in the regions that are considered to bind agonists and antagonists. This may be a reason for the difficulty in developing agonists and antagonists that are highly subtype selective.
Another feature of muscarinic receptors is the presence of a second, allosteric, binding site (Lee and El-Fakahany, 1991; Lazareno and Birdsall, 1995; Tucek and Proska, 1995; Ellis, 1997; Christopoulos et al., 1998; Holzgrabe and Mohr, 1998) . Several observations have suggested that muscarinic allosteric ligands bind to more extracellular and presumably less conserved regions of the receptor, which may allow for greater selectivities. All five muscarinic receptor subtypes are subject to allosteric modulation (Ellis et al., 1991) , and a wide array of structurally very different allosteric agents has been demonstrated to modulate the binding of conventional ligands to the five subtypes. Interestingly, among the allosteric agents that exhibit a high degree (Ͼ10-fold) of allosteric subtype selectivity, all have the greatest affinity toward the M 2 subtype and the lowest affinity toward M 5 (Ellis and Seidenberg, 2000) . With regard to the M 2 receptor, gallamine, alcuronium and a number of other allosteric ligands have been demonstrated to interact competitively with the probe obidoxime providing strong experimental evidence for a common allosteric site (Ellis and Seidenberg, 1992, 2000; Trä nkle and Mohr, 1997) .
Studies of chimeric and mutant receptors have begun to identify receptor domains and amino acids that may constitute the muscarinic allosteric site. Almost every mutagenic study published so far has focused on gallamine as the allosteric modulator (Lee et al., 1992; Ellis et al., 1993; Leppik et al., 1994; Matsui et al., 1995; Gnagey et al., 1999) . Of these studies, three have taken advantage of the subtype selectivity of gallamine by investigating chimeric substitutions. In studies with M 2 /M 5 chimeric receptors, the affinity of gallamine was exclusively enhanced, relative to M 5 , when the chimeric receptor included the M 2 third extracellular loop (Ellis et al., 1993) due to an asparagine residue at M 2 419 (Gnagey et al., 1999) . Substitutions that did not include this epitope were without effect. Nonetheless, insertion of this epitope in M 5 did not restore M 2 affinity completely. Chimeric studies including other muscarinic subtypes have demonstrated that gallamine also interacts with acidic residues in the region of the second outer loop of both the M 2 and the M 5 receptor (Leppik et al., 1994; Ellis, 1997; Gnagey et al., 1999) .
Recently, the mutagenic studies were extended to other muscarinic allosteric ligands (Ellis and Seidenberg, 2000) . In M 2 /M 5 chimeric receptors, the affinity of alcuronium, another prototype allosteric modulator, was not dependent on the source of the third outer loop of the chimera, but was exclusively sensitive to the source of the second outer loop plus flanking transmembrane regions. As in the gallamine study above, this epitope, although clearly very important, did not confer the entire M 2 affinity. Finally, even though these different allosteric agents seemed to derive affinity from different receptor epitopes, they nevertheless were shown to compete for the obidoxime-sensitive site (Trä nkle and Mohr, 1997; Ellis and Seidenberg, 2000) .
Diallylcaracurine V, structurally closely related to alcuronium, has recently been identified as an allosteric agent with a similar high binding affinity for the M 2 subtype (Zlotos et al., 2000) . The structural formulae of these two compounds look almost identical (Fig. 1 ), but their stereochemistry is considerably different (Zlotos, 2000) . Using this tool, we aimed to find out whether the stereochemical difference, relative to alcuronium, is sufficient to translate into divergent epitope sensitivities. Two other caracurine V derivatives and two flexible alkane-bisammonium-type allosteric modulators were included in our studies.
Interestingly, we found that the affinities of the caracurine V and alkane-bisammonium compounds were sensitive to common epitopes. Like alcuronium, they had higher affinity for receptors that possessed M 2 sequence in the second outer loop and flanking regions. However, their affinities were also dependent on an epitope in the seventh transmembrane domain. Using site-directed mutagenesis, we identified the essential epitope in TM7 as M 2 423 threonine. This epitope is also present in the M 4 receptor, as M 4 436 serine. We have found that these two epitopes completely account for the M 2 /M 5 selectivity of the caracurine V and alkane-bisammonium compounds. The simultaneous insertion of both M 2 epitopes into the M 5 receptor fully attained M 2 affinity. Some of these data have been reported previously in abstract form (Buller et al., 2001 ).
Experimental Procedures
Materials. Atropine sulfate was obtained from Sigma Chemical Co. (St. Louis, MO). Alcuronium was obtained from Roche Laboratories (Nutley, NJ). The bisquaternary caracurine V derivatives were synthesized as described previously . W84 was synthesized by Dr. Joachim Pfeffer (Department of Pharmacology, University of Kiel, Kiel, Germany), according to the method of Wassermann (1970) . Dimethyl-W84 was generously provided by Prof. Dr. Ulrike Holzgrabe (Trä nkle et al., 1998 Mutagenesis and Expression. The preparation of the chimeric receptors has been described previously (Ellis et al., 1993) Briefly, oligonucleotides containing the desired base changes were synthesized and allowed to anneal with pcD plasmids containing the appropriate muscarinic receptor DNA sequence. A high-fidelity polymerase then extended the synthetic oligonucleotides in a thermocycled reaction. The parental DNA was digested by a methylation-specific endonuclease before transformation of bacteria. Mutations were confirmed by sequencing. Plasmids containing the human M 2 or M 4 wildtype or mutated receptor genes were purified from bacterial cultures and transiently transfected into COS-7 cells by calcium phosphate precipitation. M 5 wild-type receptors were stably expressed in CHO cells. For binding assays, cells were harvested by scraping into 5 mM Na,K,P i buffer, pH 7.4 (PB). After homogenization and centrifugation at 50,000g for 20 min, membranes were resuspended in 5 mM PB and stored as aliquots at Ϫ70°C. Dissociation Binding Assays. Binding assays were conducted in 5 mM PB, pH 7.4, at 23°C. Membranes were prelabeled with 1 nM 3 H]NMS dissociation was then initiated by the addition of 3 M atropine, with or without the indicated concentration of allosteric modulator. After the appropriate time interval, the incubation was terminated by filtration through S&S 32 glass fiber filters (Schleicher & Schuell, Keene, NH), followed by two rinses with 40 mM PB (0°C). Membrane-bound radioactivity was determined by liquid scintillation counting. Nonspecific binding was determined by the inclusion of 3 M atropine during the labeling period.
Dissociation assays were used throughout, because they guarantee that allosteric effects are being measured; data from the dissociation assays were transformed to rate constants. The apparent rate constant (k obs ) for the dissociation of [ 3 H]NMS was determined in the presence of each indicated concentration of allosteric modulator and divided by the control rate constant (k 0 ), determined in the presence of 3 M atropine only. Curve fitting was based on a four parameter logistic function as described previously (Trä nkle and Mohr, 1997) and led to concentration-effect curves for the delay of [ 3 H]NMS dissociation, which correspond to the occupancy curves for the allosteric agent at the ligand-occupied receptor Ellis, 1997; Trä nkle et al., 1998) . Thus, the concentration inducing a half-maximal effect on radioligand dissociation (EC 50,diss ) indicates the equilibrium dissociation constant (K D ) of alloster binding to the ligand-occupied receptor and serves as a measure of affinity of the allosteric modulator for the ligand-occupied receptor. Curve-fitting was performed using the Prism program (version 3.00; GraphPAD Software, San Diego, CA).
Results
The structures of the muscarinic allosteric ligands investigated in this study are shown in Fig. 1 . All of the investigated compounds exhibited much greater allosteric affinity Epitopes Conferring Muscarinic Allosteric Selectivity toward the M 2 subtype than the M 5 subtype. The ratio of these affinities ranged from about 70-fold to more than 300-fold higher affinity for the M 2 subtype. Dissociation assays have been used extensively to ensure that only effects mediated by the allosteric binding site are being observed. The effect on ligand dissociation results from an interaction of the modulator with the ligand-occupied receptor and is thus indicative of an interaction with a recognition site distinct from the ligand binding site. The concentration-dependent effects of an allosteric ligand on [
3 H]NMS dissociation should be proportional to the occupancy of the allosteric site (Ellis, 1997) and thus reflect the affinity of the allosteric ligand at the NMS-occupied receptor . To investigate the structural basis of their subtype selectivity, the compounds have been evaluated at M 2 /M 5 chimeric receptors in which segments of low-affinity M 5 receptor were systematically replaced with analogous segments of highaffinity M 2 receptor. Subsequently, site-directed mutagenesis was performed with the aim of attributing their selectivities to specific residues.
The rates of dissociation of [ 3 H]NMS from wild-type, chimeric, and point-mutated receptors in the absence of allosteric modulator (k 0 ) are compiled in Table 1 . The rates for the wild-type and chimeric receptors are in good agreement with previously reported data (Ellis et al., 1993; Gnagey et al., 1999) . [ 3 H]NMS dissociated much more rapidly from the M 2 subtype than from M 5 . The M 2 /M 5 chimeric receptor CR3 exhibited a dissociation rate even slower than M 5 (factor of 2), whereas NMS dissociated from CR6 as fast as it did from the M 2 subtype itself. The subsequently studied point mutations in wild-type and chimeric receptors produced small but noticeable changes in k 0 that did not exceed a factor of 3 (see Discussion).
M 2 /M 5 Chimeric Receptors. In a first round, the affinity of the compounds toward the two M 2 /M 5 chimeric receptors CR3 and CR6 was investigated. CR3 contains a segment of M 2 sequence that includes the extracellular half of TM4, the second outer loop, TM5, and a portion of the third intracellular loop. CR6 contains M 2 segments at the amino and carboxyl termini embedded in the M 5 receptor (schematic diagrams are given in Fig. 2 ; for exact sequence compositions of the chimeric receptors, see Experimental Procedures).
In agreement with data from previous studies (Ellis and Seidenberg, 2000) , alcuronium displayed a greatly enhanced affinity (compared with M 5 ) toward the chimera CR3, whereas its affinity toward CR6 was only 2-fold higher than to M 5 (Fig. 2B ). The caracurine V derivative CARALL, which is structurally very closely related to alcuronium but stereochemically different from it ( Fig. 1) , exhibited not only a considerably higher affinity toward CR3 but also a strongly enhanced affinity toward CR6, relative to M 5 ( Fig. 2A) . CAR-ALL and alcuronium thus displayed remarkably divergent binding properties; in addition to an epitope in CR3, CAR-ALL obviously derives affinity from a virtually equally important epitope in CR6. Like CARALL, CARPROG (Table 2) had similar affinity for CR3 and CR6, whereas CARMETH had significantly greater affinity for CR6 than for CR3 ( Fig.   Fig. 2 Table 2 ) and dimethyl-W84 (Table 2) had higher affinity for CR3 than for CR6. Although the respective ratios vary, all of the caracurine V and alkanebisammonium compounds displayed significantly greater affinities toward both of these chimeric constructs, relative to M 5 .
Subsequent studies were performed with the chimeric receptors CR5 and CR4 (schematic diagrams in Fig. 3) . In CR5, a great part of the M 5 receptor is substituted by an M 2 segment from the N terminus of the receptor to the middle of TM4; this M 2 segment covers the entire N-terminal M 2 sequence in CR6. CR4 contains M 2 sequence from the beginning of TM6 to the end of the third extracellular loop, and this piece of M 2 sequence is completely included in the larger C-terminal M 2 segment in CR6. Thus, the chimeric substitutions in CR4 and CR5 partly overlap those of CR6. Interestingly, none of the compounds was found to have significantly greater affinity toward CR4 or CR5, relative to M 5 (see Table  2 and CARALL data in Fig. 3 ). The differential affinities of Aiming to identify a specific residue that might be responsible for the enhanced affinities toward CR6, we refined our chimeric approach to site-directed mutagenesis. Because many observations from different laboratories suggest that muscarinic allosteric ligands bind to the more extracellular region of the receptor (Jakubik and Tucek, 1994; Leppik et al., 1994; Matsui et al., 1995; Gnagey et al., 1999) , attention was directed to amino acids near the top of TM7.
Point Mutations in TM7. There is in general a high degree of conservation in TM7, but there is a striking divergence at the position corresponding to the M 2 423 threonine residue; M 5 has a histidine residue at this position (Fig. 4) . To investigate whether this threonine residue makes a crucial contribution to the M 2 selectivity over M 5 , a single point mutation was introduced into the M 2 receptor, replacing threonine 423 with histidine. This point mutation markedly reduced the affinity toward the caracurine V derivatives and the compounds W84 and dimethyl-W84 (Fig. 5A , representatively for CARALL; Table 2 ). Interestingly, the affinity of this point mutant was about the same as that of the chimera CR3.
The converse mutation, that is replacement of the corresponding M 5 478 histidine with threonine in the M 5 wild-type receptor, resulted in the reciprocal effect; the affinity toward the above compounds was considerably increased and virtually reached the affinity observed with CR6 ( Fig. 5B ; Table  2 ). These studies indicated that the M 2 423 threonine was pivotal for the higher affinity of the compounds toward CR6, relative to M 5 . This was further examined in a third point mutation that was created in the chimera CR6 itself. The TM7 threonine in CR6 was removed and "changed back" to M 5 histidine, which led to a reduction in affinity to approximately that of M 5 ( Fig. 5C ; Table 2 ). This loss of affinity was greatest for the compound that displayed the greatest gain in affinity between M 5 and CR6, CARMETH; its affinity was reduced by a factor of 244 by this mutation. There are 145 amino acids swapped from M 5 sequence to M 2 sequence in CR6 (69 amino acids at the N-terminal and 76 amino acids at the C-terminal part of the receptor). This mutant demonstrated that swapping the other 144 amino acids produced no effect if that single histidine residue remained. These findings are entirely consistent with the suggestion that the differences in the affinities of these compounds for M 5 and CR6 are due to the threonine that corresponds to M 2 423 . As noted above, the affinities of all of the compounds were found to be enhanced by an epitope in CR3. Because it contains M 5 sequence in TM7, CR3 does not possess the (M 2 423 ) threonine residue. A fourth point mutation was therefore studied in CR3. The corresponding TM7 histidine in CR3 was replaced by threonine, resulting in markedly increased affinities toward the test compounds. These affinities were consistently increased to approximately that of the M 2 receptor (Table 2 ; CARALL data also shown in Fig. 5D ). Consequently, two epitopes seem to be entirely responsible for the M 2 /M 5 selectivity of the caracurine V derivatives and the alkane-bisammonium compounds: an epitope in CR3 and M 2 423 threonine. Given the lack of significant difference between the affinities of alcuronium for M 5 and CR6 ( Fig. 2 ; Ellis and Seidenberg, 2000) , the mutations in TM7 would not be expected to alter the affinity of this ligand very much. Indeed, in marked contrast to the large and consistent effects of those point mutations on the affinities of the other compounds in this study, the effects on the affinity of alcuronium were small and inconsistent. Notably, the replacement of the TM7 histidine by threonine in CR3 did not result in an affinity near that of M 2 ; rather, it slightly decreased the affinity toward alcuronium (Table 2) . Furthermore, the opposite mutation in CR6 had no effect on the affinity of alcuronium.
Analogous Point Mutations in M 4 . At the position corresponding to M 2 423 threonine, the M 4 receptor has a serine residue (M 4 436 serine; Fig. 4 ). In view of the similarity of these amino acids, it was hypothesized that the M 4 serine would be correspondingly involved in the selectivity of M 4 over M 5 . To test this, two point mutations in the M 4 receptor were created. In one, M 4 436 serine was replaced with the corresponding (M 2 ) threonine; in the other, M 4 436 serine was replaced with (M 5 ) histidine. The compounds CARPROG, CARMETH, and dimethyl-W84 were investigated at the M 4 wild-type and mutant receptors. For all compounds, the M 4 wild-type affinity was somewhat lower than that of M 2 , but nevertheless considerably higher than that of M 5 (Fig. 6, A-C) . As expected, replacement of M 4 436 serine with threonine did not produce any significant effect on affinity toward the above compounds (Table  2) . However, analogously to M 2 423 Thr3His, the mutation M 4 436 Ser3His resulted in a marked loss of affinity toward the test compounds. There seems to be a correlation between the extent of affinity loss seen with M 4 436 Ser3His and M 2 423 Thr3His (Fig. 6 , A-C). That is, CARMETH, which displayed the highest sensitivity toward M 2 423 threonine, correspondingly showed the greatest loss in affinity (87-fold) when replacing M 4 serine with histidine. On the other hand, dimethyl-W84 was the least sensitive to the presence of M 2 423 threonine among the compounds studied and also showed the smallest loss in affinity when M 4 436 serine was mutated to histidine (4-fold). Thus, the M 2 and M 4 subtypes seem to contain a common epitope for the interaction with these allosteric ligands. This epitope is missing in M 5 and thus makes a crucial contribution to the M 2 /M 5 and the M 4 /M 5 subtype selectivities.
Discussion
Recent studies with M 2 /M 5 chimeric receptors provided evidence that structurally different allosteric ligands may derive affinity from different receptor epitopes (Ellis and Seidenberg, 2000) . We have investigated derivatives of the bisquaternary strychnos alkaloid caracurine V that are closely related to the prototype allosteric ligand alcuronium, in particular the N,NЈ-diallyl derivative CARALL (Fig. 1) . However, the stereochemistry of alcuronium and CARALL is considerably different (Zlotos, 2000) . Here, we show that a stereochemical difference is sufficient to translate into divergent epitope sensitivities. The two flexible alkane-bisammonium allosteric ligands W84 (Trä nkle et al., 1996) and dimethyl-W84 that strongly contrast the rigid and highly fused ring system of the caracurine V skeleton were included in our studies. All of these compounds were highly M 2 /M 5 selective and thus ideally suited for evaluation at M 2 /M 5 chimeric receptors to study the specific epitopes that confer their subtype selectivity. Dimethyl-W84 is of additional interest because it has been developed and is cur- rently used as a novel radioligand to label the allosteric site on M 2 receptors (Trä nkle et al., 1998; . Because the allosteric site seems to contain several potential epitopes for allosteric agent binding, we wondered whether the flexible agents could compensate for the removal of a point of attachment by switching to another conformation that would permit interaction with another epitope. If this were so, we would not expect to observe a clear-cut epitope dependence for the flexible compounds.
The affinity of alcuronium has been reported to be exclusively enhanced toward the M 2 /M 5 chimera that includes the second outer loop and flanking regions of M 2 , CR3 (Ellis and Seidenberg, 2000) . However, the affinities of CARALL and the other caracurine V derivatives were enhanced not only at CR3 but also at CR6, which includes the seventh transmembrane domain of M 2 . Thus, alcuronium and the caracurine V compounds may derive affinity from a common epitope in CR3, but they do not seem to share all points of attachment at the allosteric binding site. On the other hand, the flexible alkane-bisammonium compounds seem to be sensitive to the same epitopes that influence the binding of the caracurine V derivatives. With varying respective ratios, both groups of compounds had significantly greater affinities toward both CR3 and CR6, compared with M 5 .
Our subsequent studies at other chimeric receptors and point mutations in wild-type and chimeric receptors demonstrated that the enhanced affinity of CR6 is caused entirely by a single amino acid at the top of TM7 (i.e., M 2 423 threonine). This epitope was also found present at the corresponding position in the M 4 receptor, as M 4 436 serine. Thus, both the M 2 and M 4 subtypes seem to contain a common epitope for the interaction with these allosteric ligands; absent in M 5 , this epitope makes a crucial contribution to their M 2 /M 5 and M 4 /M 5 subtype selectivities. In addition, the data support the idea that these allosteric ligands adopt a similar orientation at the different subtypes.
In the present study we have taken the ability of the allosteric test compounds to slow the dissociation of [ 3 H]NMS as a measure of their allosteric effect. The great advantage of this approach is that it ensures that only allosteric effects are being observed. On the other hand, affinities for the free receptor cannot be extracted from these data. There are, however, some indications that suggest that there is a common binding mode for allosteric ligands at the free and NMSliganded receptors (Ellis and Seidenberg, 2000; Schröter et al., 2000) . Because [ 3 H]NMS dissociated much more rapidly from the M 2 subtype than from M 5 , one could argue that high-affinity binding of the allosteric ligand is associated with a fast dissociation and low-affinity binding with slow dissociation of [ 3 H]NMS. However, the rate of dissociation of [ 3 H]NMS from the M 2 /M 5 mutant receptors was not found to correlate with the potency of the allosteric agents. For instance, whereas M 2 and CR3 His3 Thr were very similar in terms of affinity toward the compounds (see Table 2 ), the respective half-times for the dissociation of [ 3 H]NMS are clearly different (Table 1) . A similar dichotomy can be appreciated by comparing M 5 and CR6 Thr3 His. Several reasons have been previously discussed why rate constants (k 0 ) are not expected to be consistently tied to particular receptor epitopes (Ellis et al., 1993; Ellis and Seidenberg, 2000) . Nonetheless, a certain consistency was observed in the way the threonine/histidine point mutations affected the respective Thr revealed exactly the same NMS affinity as for the M 5 wild-type receptor (data not shown). Indeed, the M 2 /M 3 chimeric receptor "m3N2" has the corresponding threonine residues in TM1 (from M 3 ) and in TM7 (from M 2 ), yet has been reported to bind [ 3 H]NMS with high affinity (Wess et al., 1990) . In addition, the M 4 wild-type receptor has a serine residue at the corresponding position in TM7 (M 4 436 serine) and a threonine residue in TM1 (M 4 39 threonine). Thus, although it seems likely that the findings of Liu et al. (1995) do reflect interhelical interactions, the conflict may be unique to the particular receptor constructs that they studied.
Nearly every mutagenic study of the muscarinic allosteric binding site that has been published to date has focused on gallamine as the primary allosteric modulator (Lee et al., 1992; Ellis et al., 1993; Leppik et al., 1994; Matsui et al., 1995; Gnagey et al., 1999) . Matsui et al. (1995) mutated conserved aromatic and polar residues in the extracellular loops and loop/transmembrane helix interfaces of the M 1 receptor. This study found that the M 1 400 tryptophan residue at the junction of o3/TM7 was important for the binding of gallamine and that mutation to alanine reduced gallamine's affinity by about 10-fold. This tryptophan is conserved in all five subtypes and is adjacent to the M 2 423 threonine and M 4 436 serine residues identified in the present study (Fig. 4) . With regard to gallamine's subtype selectivity, previous studies with M 2 /M 5 chimeric receptors have shown that gallamine derives affinity for the M 2 subtype from a region within the o3-chimera CR4 (Ellis et al., 1993) , to which, so far, no other allosteric ligand has been found to be sensitive. Subsequent studies attributed gallamine's CR4 interaction to an asparagine residue in the third extracellular loop (i.e., M 2 419 asparagine) (Gnagey et al., 1999) , which lies four residues away from M 2 423 threonine. Thus, within this region of the receptor, the presently investigated ligands and gallamine seem to derive affinity from receptor loci that are near each other but not identical.
On the other hand, the investigated ligands were found to have enhanced affinity toward the chimeric receptor CR3 that included the M 2 second extracellular loop (o2) plus surrounding regions. In a study by Leppik et al. (1994) , the binding of gallamine was also shown to be sensitive to an Epitopes Conferring Muscarinic Allosteric Selectivity epitope in o2. The authors identified a four-residue sequence in o2 of the M 2 receptor (EDGE), which when mutated to its M 1 counterpart resulted in a significantly reduced affinity toward gallamine. However, gallamine had been found to bind equally well to the M 5 receptor and to the chimeric receptor CR3, which includes M 2 sequence in this region (Ellis et al., 1993) . This apparent discrepancy has been explained by experiments that indicate that both the M 5 and M 2 receptor contain the essential epitope in this region, whereas M 1 lacks it (Gnagey et al., 1999) . Nonetheless, this also implies that the ligands investigated in the present study, which did display significantly greater affinity toward CR3 than toward M 5 , presumably derive affinity from an epitope that involves residues other than those that affect gallamine's affinity in this region of the receptor. This situation may be similar to that described above for the o3/TM7 region of the receptor. We are currently investigating smaller chimeric inserts to attempt to identify the responsible epitope(s) within CR3.
The present study confirms the suggestion that muscarinic allosteric ligands interact with different receptor loci. However, despite this apparent complexity, two main regions of the receptor stand out from which allosteric agents seem to derive affinity: 1) the second outer loop and/or adjacent regions of TM4 and TM5; and 2) the junction between the third outer loop and TM7. At the position corresponding to M 2 423 threonine, the M 4 receptor was found to contain an analogous epitope for the interaction with these compounds (i.e., M 4 436 serine). These findings are furthermore consistent with the notion that muscarinic allosteric ligands bind to regions that are located more extracellularly, relative to the classical ligand binding site. In TM7, Wess et al. (1991) identified two conserved tyrosine residues that seemed to be critical for muscarinic agonist binding. Relative to M 2 423 threonine or M 4 436 serine, these tyrosine residues are located about one and two helical turns down toward the intracellular side of the receptor. Recent studies have indicated the presence of a second muscarinic allosteric site, based on the lack of competition between two classes of allosteric ligands (Lazareno et al., 2000) . The structural details of this site have not yet been investigated, but in view of the lack of sensitivity of the compounds investigated in the present study to substitutions in the N-terminal half of the receptor (i.e., CR5), one may speculate that this second allosteric site may be located in the N-terminal part of the receptor.
In summary, we have investigated a number of highly subtype-selective allosteric compounds at M 2 /M 5 mutant receptors. The stereochemical difference between alcuronium and CARALL was found to translate into divergent epitope sensitivies. On the other hand, the rigid caracurine V derivatives and the flexible alkane-bisammonium compounds seemed to interact with the same receptor epitopes. In fact, the flexible compounds exhibited a substantially inflexible behavior with regard to their affinities toward the recombinant receptors; the respective mutations led to clear and predictable affinity shifts, indicating that they do not compensate for the removal of a point of attachment by changing their conformations. For the different allosteric ligands investigated in this study, two epitopes (the o2 region and M 2 423 threonine at the top of TM7) are sufficient to account fully for their M 2 selectivity over M 5 .
